

# Keyword index

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), 590

## A

ABO-incompatible, 1210  
ABO-incompatible renal transplantation, 716  
accessory liver lobe, 467  
accommodation, 716  
acellular matrix, 727  
activation, 15  
acute allograft rejection, 676  
acute cellular rejection, 1147  
acute humoral rejection, 401  
acute rejection, 36, 157, 226, 385  
adefovir, 879  
adenosine, 289  
adherence, 960  
adhesion molecules, 101, 215, 226, 333, 1166  
adjuvant therapy, 992  
adriamycin, 992  
adult, 396  
adult-to-adult living donor liver transplantation, 1240  
adverse effects, 1072  
African-Americans, 419  
alcohol consumption, 1292  
alcohol dependence, 1292  
alcoholic cirrhosis, 1292  
alcoholic liver disease, 491  
alginate, 1001  
allogeneic transplants, 412  
allograft rejection, 101  
allografts, 206, 237  
allo-immune rejection, 800  
aminotransferases, 1302  
amyloidosis, 366  
anaplastic carcinoma, 1109  
anatomical variation, 467  
anesthesia, 396  
angiogenesis, 89  
angioplasty, 556  
animal model, 101  
anti-CD4 treatment, 854  
antigenemia, 43

anti-hepatitis B virus immunoglobulins, 186  
anti-lymphocyte serum, 1366  
antioxidants, 992  
antithymocyte globulin, 226  
antiviral treatment, 941  
anxiety, 954  
aorta transplantation, 735  
aplastic anaemia, 487  
apoptosis, 1079  
arterial hypertension, 967  
arterial reconstruction, 499  
arterial wall, 1346  
autotransfusion, 1236  
azathioprine, 157, 590

## B

bacteriuria, 177  
Banff classification, 36  
basiliximab, 36  
bile duct complication, 627  
bile duct necrosis, 56  
biliary complication, 1240  
bioelectrical impedance analysis, 541  
bioequivalence, 371  
bladder augmentation, 884  
blood levels, 1152  
blood pressure, 22, 806  
body composition, 246, 541  
body mass index, 309, 1231  
bone marrow transplantation, 125  
bone metabolism, 1028  
brain death, 15  
bronchial graft, 1100  
bronchoscopy, 562  
B-type natriuretic peptide, 169  
Budd-Chiari syndrome, 1376

## C

C2 monitoring, 116  
C<sub>2</sub> monitoring, 768  
C3 split products, 475  
2C transgenic mouse, 101  
cadaveric donors, 709  
cadaveric kidney transplantation, 419  
calcineurin inhibitors, 140

campesterol, 221  
cancer, 52, 89, 360, 1280  
cardiac allograft vasculopathy, 1113  
cardiac cirrhosis, 697  
cardiac transplantation, 390  
cardiovascular, 379  
cardiovascular disease, 681  
case-control, 309  
catheter drainage, 721  
C4d, 676, 800  
cell adhesion molecules, 475  
cell transfer, 1187  
ceruloplasmin, 651  
Charlson comorbidity index, 1248  
chemokine, 844  
chemokine receptor, 676  
chemokines, 444, 676  
children, 36  
Chinese, 283  
cholestanol, 221  
cholestasis, 125, 697  
cholesterol, 524, 806  
chondrocytes, 727  
chronic allograft dysfunction, 151  
chronic allograft nephropathy, 131, 668, 800, 863, 981, 1175  
chronic rejection, 506, 532, 743, 800, 1100, 1166  
chronic transplant dysfunction, 735  
chyloperitoneum, 1378  
chyloous ascites, 1378  
ciclosporin, 816  
clinical outcome, 326, 768  
clinical transplantation, 596  
coagulation, 929, 1258  
cobalamin, 29  
cold storage, 657  
collagens, 506  
comorbidity, 1248  
complement, 475  
complement split product, 800  
compliance, 1072  
complication, 584, 929  
complications, 548  
complications of clinical transplantation, 596  
computed tomography volumetry, 915

- concentration-dose ratio, 1152  
 coping, 954  
 corneal xenotransplantation, 854  
 coronary artery disease, 256  
 coronary disease, 313  
 coronary heart disease, 967  
 cost analysis, 437  
 costimulatory molecules, 1197  
 cross-sectional observational study, 169  
 cryopreservation, 750, 1346  
 CT-angiography, 1134  
 CTLA4Ig, 1187  
 CXCR3, 676  
 cyclooxygenase 2, 871  
 cyclosporin, 289  
 cyclosporin A, 193, 470, 668  
 cyclosporine, 261, 371, 379, 458, 524, 619, 768, 806, 871, 1028  
 cyclosporine A, 992, 1328  
 cyclosporine withdrawal, 22  
 cystic fibrosis, 246  
 cytokine, 681  
 cytokines, 226, 854, 1067, 1158  
 cytomegalovirus, 43, 735, 743, 941, 1318
- D**
- decision making, 519  
 delayed graft function, 596  
 dendritic cells, 412, 1366  
 deoxyribonucleic acid, 412  
 depression, 954  
 determinants, 169  
 diabetes, 379, 619  
 diabetes mellitus, 967, 1152  
 diabetic retinopathy, 619  
 diarrhea, 470  
 DNAemia, 43  
 donation, 709  
 donation rates, 1275  
 donor age, 902  
 donor evaluation, 1134  
 donor leucocytes, 487  
 donor treatment, 15  
 donor-specific, 1286  
 donor-specific antibodies, 532  
 Doppler ultrasound, 350  
 double kidney transplantation, 453  
 drug administration, 89  
 drug holidays, 960  
 drug-eluting stent, 1113  
 duct-to-duct biliary reconstruction, 1240
- E**
- early graft dysfunction, 1079  
 echocardiography, 303
- economic evaluation, 437  
 electronic event monitoring, 960  
 encapsulation, 1001  
 endomyocardial biopsy, 313  
 endothelial cells, 475  
 endothelin-1, 341  
 endothelin, 429  
 end-stage renal disease, 1036  
 enteric drainage, 296  
 enzyme-linked immunosorbent assay, 532, 716  
 eosinophilia, 1147  
 Epstein-Barr virus, 835, 1304  
 estrogen receptor, 1010  
 expanded donor pool, 709  
 experimental liver transplantation, 56  
 extracellular matrix, 1175  
 extracellular water, 541
- F**
- familial amyloidotic polyneuropathy, 111  
 Fas, 1001  
 femoral arteries, 1346  
 fibrinolysis, 256  
 fibrosing cholestatic hepatitis, 902  
 fibrosis, 506, 1175  
 Fischer-to-Lewis rat model, 863  
 FK506, 193  
 FK778, 215  
 flow cytometry, 163  
 flucloxacillin, 487  
 focal segmental glomerulosclerosis, 458  
 folate, 29  
 fulminant hepatic failure, 487  
 functional weight, 453  
*Fusarium*, 613
- G**
- gallbladder, 52  
 ganciclovir, 835, 941  
 gastroduodenal artery steal syndrome, 350  
 gastrointestinal bleeding, 296  
 gastrointestinal complications, 643  
 gene array, 1010  
 general, 396  
 generic formulation, 371  
 gingival hyperplasia, 816  
 glomerulosclerosis, 453  
 glucose metabolism, 1361  
 graft acceptance, 1187  
 graft dysfunction, 577  
 graft loss, 385  
 graft survival, 22, 703, 854
- graft vessel disease, 908  
 graft-versus-host-disease, 125  
 growth factors, 743
- H**
- haemorrhage, 929  
 haemostasis, 1036  
 heart, 657  
 heart failure, 697  
 heart transplantation, 29, 116, 169, 283, 303, 326, 437, 697, 908, 1113, 1197, 1280, 1318  
 hematopoietic stem cell transplantation, 1215  
 heme oxygenase, 341  
 hemodialysis, 541, 785  
 hemostasis, 256  
 heparin-induced thrombocytopenia, 664  
 hepatectomy, 548, 915  
 hepatic artery, 499  
 hepatic microcirculation, 429  
 hepatic vein, 556  
 hepatic VOD, 1215  
 hepatitis B cirrhosis, 879  
 hepatitis B virus, 186  
 hepatitis C, 73, 902  
 hepatitis C virus patients, 1336  
 hepatocarcinoma, 1236  
 hepatocellular carcinoma, 278, 408, 992  
 hepatocyte, 750, 1001  
 high-performance liquid chromatography, 354  
 HLA antibodies, 1286  
 homocysteine, 29  
 human, 584  
 human leukocyte antigen antibodies, 532  
 humoral rejection, 532, 800, 1298  
 hydrothorax, 672  
 hyperlipidemia, 816  
 hypertension, 816  
 hypertrichosis, 816  
 hypoxia/reoxygenation, 475  
 hypoxia-reoxygenation, 444
- I**
- immune and biological response, 78  
 immune cells, 1100  
 immunohistochemistry, 313  
 immunologic tolerance, 95  
 immunoreactivity, 1361  
 immunosuppression, 2, 89, 95, 116, 261, 309, 461, 470, 596, 768, 894, 1072, 1121, 1158, 1304, 1361, 1366  
 immunosuppressive drug monitoring, 140

## Keyword index

- immunosuppressive drugs, 360  
immunosuppressive regimen, 1226  
immunosuppressive therapy, 643  
*in situ* perfusion, 1142  
*in vitro* model, 727  
indication to liver transplantation, 491  
indirect pathway, 237  
indoleamine 2,3-dioxygenase, 95  
induction therapy, 1280  
infection, 360, 562, 584, 1048, 1166  
infective endocarditis, 690  
inflammation, 198, 949  
informed consent, 1275  
innate immunity, 1366  
inosine monophosphate dehydrogenase, 401  
insulin sensitizer, 483  
intensive care unit, 1356  
interleukin 2, 193  
interleukin  $\beta$ , 475  
intermittent hypoxia, 444  
international normalized ratio, 65  
intima-media thickness, 256  
intracellular adhesion molecule 1, 333  
intracellular water, 541  
intraoperative contamination, 824  
intra-portal infusion, 923  
ischemia/reperfusion, 198  
ischemia/reperfusion injury, 1258  
ischemia-reperfusion, 1079  
islet isolation, 584  
islet transplantation, 101, 828, 1226  
islet-antibodies, 1361
- J**  
Jehovah, 929  
juvenile rheumatoid arthritis, 366
- K**  
keratoplasty, 193, 703  
kidney, 657, 743  
kidney clinical, 1121  
kidney function, 111  
kidney transplant, 289, 333, 1036, 1302  
kidney transplantation, 36, 131, 157, 226, 256, 366, 385, 401, 506, 532, 541, 619, 785, 806, 884, 975, 981, 1019, 1109, 1152, 1266, 1309  
kidney transplants, 1286  
Kupffer cell, 844  
Kupffer cells, 429  
kynurenine, 95
- L**  
lamb  $\times$  porcine, 1100  
lamivudine, 186, 879  
lamivudineR-mutants hepatitis B virus, 879  
laparoscopic living renal donation, 1019  
laparoscopy, 1019, 1378  
laser-Doppler flowmetry, 296  
late post-transplant phase, 169  
lathosterol, 221  
left ventricular dysfunction, 303  
linked, 423  
lipid metabolism, 967  
lipid peroxidation, 844  
live kidney donor, 975  
liver, 318, 396, 657, 750, 1302  
liver cirrhosis, 672  
liver donation, 577  
liver failure, 697  
liver function tests, 548  
liver ischaemia/reperfusion, 604  
liver nonparenchymal, 206  
liver regeneration, 1061  
liver sinusoidal endothelial cells, 206, 237  
liver steatosis, 577  
liver synthetic function, 1061  
liver transplant, 461, 556, 879, 902  
liver transplantation, 52, 65, 73, 111, 125, 186, 206, 221, 246, 278, 350, 396, 437, 467, 487, 491, 513, 572, 627, 672, 724, 811, 835, 929, 937, 941, 967, 992, 1061, 1147, 1292, 1298, 1328, 1382  
liver trauma, 724  
liver/kidney transplantation, 78  
living donation, 975  
living donor, 929, 1378  
living donor adult liver transplantation, 923  
living donor liver transplant, 278  
living donor liver transplantation, 794, 915, 1240  
living donors, 1309  
living kidney donation, 519  
living related kidney transplantation, 1134  
living renal donor, 1019  
living-donor liver transplantation, 408  
living-related donor liver transplantation, 47  
living-related liver transplantation, 499, 651  
long-term graft function, 1067  
long-term outcome following liver transplantation, 491  
lung, 198, 657, 1100  
lung transplantation, 562, 954, 1166, 1203, 1318  
Ly-49A, 1090  
Ly-49D, 1090  
Ly-49G2, 1090  
lymphocele, 721  
lymphocytes, 1158  
lymphoma, 835
- M**  
macroangiopathy, 1054  
macrophage, 844  
macrophage migration inhibitory factor, 1203  
macrophages, 412  
malignancy, 283, 779  
Mammalian Target of Rapamycin (mTOR) inhibitors, 140  
marginal donor, 453  
marginal graft, 1328  
matrix metalloproteinases, 506  
medication noncompliance, 960  
medullary thick ascending limb, 871  
MELD, 577  
mesothelium, 1376  
methionine synthase reductase, 29  
methylenetetrahydrofolate reductase, 29  
mice, 444  
microbial contamination, 584  
microcirculation, 1079  
microsurgical technique, 56  
miniature swine, 78  
mixed lymphocyte culture, 1067  
mizoribine, 401, 590  
model for end-stage liver disease, 572  
Model for End-stage Liver Disease score, 65  
monitoring, 396, 806  
monocytes, 1366  
mortality, 65, 390, 1231  
mortality rates, 1275  
mRNA expression, 1197  
multidetector-row computed tomography, 499  
multi-organ procurement, 657  
mycophenolate acid, 590  
mycophenolate mofetil, 36, 140, 157, 590, 703, 1286
- N**  
nocardiosis, 1048  
nasopharyngeal temperature, 396  
neoplastic recurrence, 1236  
Neoral, 768  
nephrectomy, 1378  
neutropenia, 487  
neutrophil, 844

- new-onset diabetes mellitus, 483  
 nitric oxide, 854, 871  
 NK cell, 1090  
 NK cells, 1366  
 noncompliance, 1121  
 nonheart beating donor, 724  
 nonheart-beating donor, 333, 1142  
 nonheart-beating donors, 596  
 N-telopeptides, 1028  
 nude rats, 981  
 nutritional status, 246
- O**
- obesity, 461, 1231  
 obliterative bronchiolitis, 1166  
 obstructive bronchiolitis, 1203  
 OKT3, 835  
 older donor, 73  
 old-living donors, 1266  
 operating room extubation, 1328  
 organ, 396  
 organ donation, 828, 1275  
 organ preservation and procurement, 1346  
 organ transplant, 43  
 organ transplantation, 360, 371, 664  
 orthotopic, 318  
 orthotopic liver transplantation, 1231, 1258  
 outcome, 709, 1121, 1248, 1266  
 outcomes, 949  
 outpatient surgery, 721  
 overweight, 967  
 ozone, 604
- P**
- paediatric, 811  
 pancreas, 657  
 pancreas transplantation, 296, 619, 828, 1356, 1361  
 pancreas-kidney transplantation, 1054  
 panel reactive antibody, 163  
 patient, 396  
 patient survival, 1248  
 pediatric, 360, 396  
 pediatric heart transplantation, 1210  
 pediatric recipients, 785  
 perfusion fluid, 824  
 peripheral blood mononuclear cells, 590  
 peritoneal dialysis, 785  
 peritonitis, 613  
 piggyback, 318  
 piggy-back technique, 1328  
 plasmapheresis, 1298  
 platelet aggregation, 1258  
 platelets, 1036  
*Pneumocystis carinii*, 562  
 polycystic liver disease, 513  
 polymerase chain reaction, 186  
 polyomavirus, 1304  
 polyunsaturated fatty acids, 524  
 poor compliance, 755  
 porcine animal model, 198  
 porcine endogenous retrovirus, 894  
 porcine liver transplantation, 429  
 portal hypertension, 1382  
 portal vein thrombosis, 750  
 portal venous injection, 237  
 postmortal donation, 519  
 postoperative complication, 915, 1378  
 postoperative complications, 1356  
 post-transplant diabetes mellitus, 309  
 post-transplant infections, 824  
 post-transplant lymphoproliferative disorder, 1304  
 post-transplant malignancy, 89  
 pp65 antigen test, 941  
 preconditioning, 198, 444  
 prednisone, 524  
 preservation solution, 657  
 pressure–diameter, 1346  
 presumed consent, 1275  
 primary biliary cirrhosis, 794, 937  
 primary graft nonfunction, 429  
 primary sclerosing cholangitis, 937  
 prognosis, 1248  
 proliferation, 1158  
 prophylaxis, 941  
 prostaglandin E2, 871  
 protein synthesis, 604  
 prothymosin alpha, 1010  
 protocol biopsy, 131, 668  
 psychological outcome, 975  
 psychology, 519  
 psychosocial support, 755  
 pulmonary function, 246
- Q**
- quality of life, 519, 975, 1309  
 questionnaires, 1309
- R**
- radial artery graft, 408  
 RANTES, 333  
 rapamycin, 89, 289, 366  
 rapamycin rescue therapy, 151  
 rat, 341, 735  
 rat aorta transplantation, 1010  
 rat liver transplantation, 1079, 1187  
 real-time PCR, 835  
 recipients, 779  
 reconstruction of the hepatic artery, 56  
 recurrent glomerulonephritis, 458  
 rejection, 116, 303, 703, 949, 1067  
 relapse, 1292  
 relapse into alcohol consumption, 491  
 renal, 341, 949  
 renal allografts, 824  
 renal function, 22, 1226  
 renal transplant, 309, 1248  
 renal transplantation, 36, 140, 163, 177, 261, 437, 458, 483, 643, 1067, 1142, 1304  
 renal transplantation complications, 643  
 rescue therapy, 401  
 restenosis, 1113  
 right heart failure, 326  
 right lobe, 47  
 risk factor, 15  
 risk factors, 309, 908, 941, 1152  
 rodents, 423  
 rosiglitazone, 483  
 rotavirus, 470  
 routine biopsies, 36  
 Roux-en-Y hepaticojejunostomy, 1240
- S**
- screening, 779  
 selection criteria, 709  
 self-rated health, 1072  
 Sertoli, 1001  
 serum creatinine, 385, 785  
 serum osteocalcin, 1028  
 severe recurrence, 902  
 short interference RNA, 1203  
 simultaneous pancreas and kidney transplantation, 755  
 sirolimus, 22, 261, 354, 458, 524, 1028, 1302  
 sitosterol, 221  
 skin, 360  
 small for size graft injury, 923  
 small vessel disease, 908  
 solid organ transplantation, 613, 690, 960  
 split, 811  
 steatosis, 915  
 steroid, 1147  
 steroid-free, 1336  
 steroid withdrawal, 36, 157  
 stress, 954  
 subclinical rejection, 131  
 suppression, 423  
 surgery, 396, 929, 1158  
 surgical technique, 513  
 survival, 937  
 survival analysis, 1231

## Keyword index

### T

T cells, 1158  
T lymphocytes, 981  
tacrolimus, 36, 157, 261, 289, 379, 419, 470, 668, 816, 1152, 1215, 1336  
T-cell cytotoxicity, 863  
techniques, 1346  
tenofovir, 879  
Th1/Th2 response, 226  
therapeutic drug monitoring, 140  
three-dimensional angiography, 499  
thymoglobuline, 1280  
timing for liver transplantation, 491  
tissue banking, 1346  
tissue inhibitors of matrix metalloproteinases, 506  
tissue transplantation, 1346  
tolerance, 2, 206, 237, 423, 894  
trachea replacement, 727  
tracheal epithelial cells, 727  
transforming growth factor beta, 1175  
transforming growth factor- $\beta$ 1, 668  
transfusion, 548, 929  
transjugular portosystemic stent shunt, 1382  
transplant, 2, 1001

transplant arteriopathy, 863  
transplant arteriosclerosis, 735, 1010  
transplant capillaropathy, 863  
transplant glomerulopathy, 800, 863  
transplant outcome, 975  
transplantation, 15, 215, 313, 318, 341, 379, 423, 470, 584, 613, 681, 750, 779, 894, 1048, 1072, 1236  
transpulmonary pressure gradient, 390  
treatment outcome, 1356  
triglycerides, 524  
tryptophan, 95  
tumor transmission, 1109  
type 1 diabetes, 1054

### U

ultraviolet detection, 354  
United Network for Organ Sharing status, 65  
updated Mayo risk score, 794  
urinary tract infection, 177  
urine interleukin-6, 177  
urine interleukin-8, 177  
urine soluble interleukin-2 receptor, 177  
urine soluble interleukin-6 receptor, 177

urine soluble interleukin-1 receptor antagonist, 177

### V

vaginal haemorrhage, 1382  
vaginal varices, 1382  
vascular cell adhesion molecule 1, 333  
vascular graft, 1376  
vena cava preservation, 513  
vessels, 1346  
viral cirrhosis, 1328  
viscoelasticity, 1346  
vitamin D, 1175  
voriconazole, 613

### W

waiting list, 779, 954  
weight gain, 461  
whole blood, 354  
von Willebrand factor, 1258  
Wilson's disease, 651

### X

xenotransplantation, 894, 1100  
xenozoonoses, 894